David Olmos was born in Malaga in 1977. He received his MD from the Universidad de Malaga in 2001 and subsequently trained as Medical Oncologist at the Hospital Universitario Virgen de la Victoria, Malaga. He also received his PhD from the Universidad de Malaga for his work in expression profiling of stroma cells and malignant cells in Hodgkin’s lymphoma. He has also obtained a University degree in statistics applied to Health Sciences and a Master degree in Biostatistics and Research Methodology from the Universidad Autónoma de Barcelona.
After completing his oncology training in 2006, David joined The Royal Marsden Hospital-The Institute of Cancer Research, United Kingdom, to train as Clinician Scientist. During the 6 years he spent in this comprehensive cancer centre David worked in Professor Johann de Bono’s laboratory developing the methodologies for isolation and characterisation of circulating tumoral cells, as well as in the molecular characterisation and profiling of Castration Resistant Prostate Cancers. He also complemented his laboratory training with a clinical fellowship at the Drug Development Unit lead by Professors Stan Kaye, Johann de Bono and Ian Judson, where he was involved in more than 100 Phase I, II and III trials including those of the novel active drugs abiraterone, enzatulamide, cabizitaxel, figitumumab and olaparib.
David has published over 60 papers in peer-reviewed journals, including important methodological work in Phase I patient selection, early clinical trials methodology, and Prostate Cancer Biomarkers
David has received several grants and awards including an ESMO Research Fellowship (2006-2007), a SEOM Translational Research Fellowship (2009-2010), a GSK-AACR scholarship (2008), three ASCO merit awards (2008, 2009 and 2010) and three ESMO merit awards (2008, 2010 and 2012). David has recently joined the clinical Research programme at CNIO in September 2012 supported by an “Asociación Española Contra el Cáncer (AECC) – Beca de Retorno” grant. At CNIO, he leads the Prostate Cancer and Genitourinary Tumours Clinical Research Unit with the support of the “Fundación CRIS contra el cáncer”.